PT  - JOURNAL ARTICLE
AU  - Ivan A. Molodtsov
AU  - Evgenii Kegeles
AU  - Alexander N. Mitin
AU  - Olga Mityaeva
AU  - Oksana E. Musatova
AU  - Anna E. Panova
AU  - Mikhail V. Pashenkov
AU  - Iuliia O. Peshkova
AU  - Alsalloum Almaqdad
AU  - Walaa Asaad
AU  - Anna S. Budikhina
AU  - Aleksander S. Deryabin
AU  - Inna V. Dolzhikova
AU  - Ioanna N. Filimonova
AU  - Alexandra N. Gracheva
AU  - Oxana I. Ivanova
AU  - Anastasia Kizilova
AU  - Viktoria V. Komogorova
AU  - Anastasia Komova
AU  - Natalia I. Kompantseva
AU  - Denis A. Lagutkin
AU  - Yakov A. Lomakin
AU  - Alexandra V. Maleeva
AU  - Elena V. Maryukhnich
AU  - Afraa Mohammad
AU  - Vladimir V. Murugin
AU  - Nina E. Murugina
AU  - Anna Navoikova
AU  - Margarita F. Nikonova
AU  - Leyla A. Ovchinnikova
AU  - Natalia V. Pinegina
AU  - Daria M. Potashnikova
AU  - Elizaveta V. Romanova
AU  - Aleena A. Saidova
AU  - Nawar Sakr
AU  - Anastasia G. Samoilova
AU  - Yana Serdyuk
AU  - Naina T. Shakirova
AU  - Nina I. Sharova
AU  - Savely A. Sheetikov
AU  - Anastasia F. Shemetova
AU  - Liudmila Shevkova
AU  - Alexander V. Shpektor
AU  - Anna Trufanova
AU  - Anna V. Tvorogova
AU  - Valeria M. Ukrainskaya
AU  - Anatoliy S. Vinokurov
AU  - Daria A. Vorobyeva
AU  - Ksenia V. Zornikova
AU  - Grigory A. Efimov
AU  - Musa R. Khaitov
AU  - Ilya A. Kofiadi
AU  - Alexey A. Komissarov
AU  - Denis Y. Logunov
AU  - Nelli B. Naigovzina
AU  - Yury P. Rubtsov
AU  - Irina A. Vasilyeva
AU  - Pavel Volchkov
AU  - Elena Vasilieva
TI  - SARS-CoV-2 specific T cells and antibodies in COVID-19 protection: a prospective study
AID  - 10.1101/2021.08.19.21262278
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.19.21262278
4099  - http://medrxiv.org/content/early/2021/10/06/2021.08.19.21262278.short
4100  - http://medrxiv.org/content/early/2021/10/06/2021.08.19.21262278.full
AB  - Rapid spread of COVID-19 pandemic made a substantial share of the world population immunised by SARS-CoV-2 antigens. Infection induces the development of virus-specific antibodies and T cells. Ample evidence on the antibody-mediated protection is contrasted by the elusive role of T cells in preventing infection. To explore the impact of T cells and to quantify the protective levels of the immune responses we conducted a large prospective study: 5,340 Moscow residents were evaluated for the antibody and cellular immune responses to SARS-CoV-2 and monitored for COVID-19 up to 300 days. The antibody and cellular responses were tightly interconnected, their magnitude inversely correlated with infection probability. Similar maximal level of protection was reached by individuals positive for both types of responses and by individuals with antibodies alone. Meanwhile, T cells in the absence of antibodies provided an intermediate level of protection. The real-world data on the protective effects of T cells have important implications for T cell immunology and development of the strategies to fight the pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04898140Funding StatementThe authors thank the Moscow Department of Healthcare for the help in organization of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Moscow City Ethics Committee of the Research Institute of the Organization of Health and Healthcare Management and performed according to the Helsinki Declaration. All participants provided their written informed consent. The study was registered on ClinicalTrials.gov (Identifier: NCT04898140).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article and supplementary materials